EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2466
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma ; volume:19 ; number:1 ; day:11 ; month:11 ; year:2019 ; pages:1-10 ; date:12.2019
BMC pulmonary medicine ; 19, Heft 1 (11.11.2019), 1-10, 12.2019
- Creator
-
Colombino, Maria
Paliogiannis, Panagiotis
Cossu, Antonio
Santeufemia, Davide Adriano
Sini, Maria Cristina
Casula, Milena
Palomba, Grazia
Manca, Antonella
Pisano, Marina
Doneddu, Valentina
Palmieri, Giuseppe
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12890-019-0964-x
- URN
-
urn:nbn:de:101:1-2020030821175017546860
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Colombino, Maria
- Paliogiannis, Panagiotis
- Cossu, Antonio
- Santeufemia, Davide Adriano
- Sini, Maria Cristina
- Casula, Milena
- Palomba, Grazia
- Manca, Antonella
- Pisano, Marina
- Doneddu, Valentina
- Palmieri, Giuseppe
- SpringerLink (Online service)
Other Objects (12)
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
KRAS- und BRAF-Mutationen im lokal fortgeschrittenen Rektumkarzinom
c-Met als prognostischer Biomarker im EGFR-mutierten nichtkleinzelligen Lungenkarzinom
Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits
Predictive role of [18F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Vergleich des KRAS/BRAF-Mutationsstatus zwischen Primärtumoren und Metastasen kolorektaler Karzinome
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
KRAS- und BRAF-Mutationen im lokal fortgeschrittenen Rektumkarzinom
c-Met als prognostischer Biomarker im EGFR-mutierten nichtkleinzelligen Lungenkarzinom
Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits
Predictive role of [18F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Vergleich des KRAS/BRAF-Mutationsstatus zwischen Primärtumoren und Metastasen kolorektaler Karzinome
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
KRAS- und BRAF-Mutationen im lokal fortgeschrittenen Rektumkarzinom
c-Met als prognostischer Biomarker im EGFR-mutierten nichtkleinzelligen Lungenkarzinom
Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits
Predictive role of [18F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells